The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

GSK, Empirico enter license agreement for oligonucleotide candidate to treat respiratory diseases

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

GSK and Empirico Inc. announced that they have entered into a worldwide exclusive license agreement for EMP-012, a highly selective first- and potentially best-in-class siRNA, a type of oligonucleotide.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Blenrep combination shows OS benefit in MM

GSK plc announced statistically significant and clinically meaningful overall survival results from a planned interim analysis of the DREAMM-7 trial evaluating Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone versus daratumumab in combination with bortezomib plus dexamethasone as a second line or later treatment for relapsed or refractory multiple myeloma. 
In Brief

Victor Ambros and Gary Ruvkun share 2024 Nobel Prize in Physiology or Medicine

Victor AmbrosPhoto credit: Niklas Elmehed © Nobel Prize OutreachGary RuvkunPhoto credit: Niklas Elmehed © Nobel Prize OutreachVictor Ambros and Gary Ruvkun were jointly awarded the 2024 Nobel Prize in Physiology or Medicine from the Nobel Assembly at the Karolinska Institutet. The two scientists are being honored for their discovery of microRNA and its role in post-transcriptional gene regulation.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account